Institutional members access full text with Ovid®

Share this article on:

General Health Issues in Multiple Sclerosis: Comorbidities, Secondary Conditions, and Health Behaviors

Marrie, Ruth Ann MD, PhD; Hanwell, Heather PhD

doi: 10.1212/01.CON.0000433284.07844.6b
Review Articles

Purpose of Review Comorbid conditions, secondary conditions, and health behaviors are increasingly recognized to be important factors influencing a range of outcomes in multiple sclerosis (MS). This review discusses the most common comorbidities experienced in MS, their impact on clinical outcomes, and the impact of health behaviors. Osteoporosis is a common secondary condition in MS that will be discussed along with vitamin D insufficiency.

Recent Findings Mental comorbidity is common in MS; depression has a lifetime prevalence of 50%, while anxiety has a lifetime prevalence of 36%. Physical comorbidity is also common, with the most frequently reported conditions including hyperlipidemia, hypertension, arthritis, irritable bowel syndrome, and chronic lung disease. Fracture risk is increased among patients with MS because of an increased risk of osteoporosis and propensity for falls. Vitamin D insufficiency is common and may contribute to increased fracture risk and increased disease activity. Comorbidities and smoking are associated with diagnostic delays, increased disability progression, lower health-related quality of life, and lower adherence to treatment.

Summary Physical and mental comorbidity and adverse health behaviors are common in patients with MS. Comorbidities and health behaviors are associated with adverse outcomes in MS and should be considered in the assessment and management of patients with MS.

Address correspondence to Dr Ruth Ann Marrie, Health Sciences Center, GF-533, 820 Sherbrook Street, Winnipeg, MB Canada, R3A 1R9,

Relationship Disclosure: Dr Marrie receives research funding from Sanofi-Aventis for a clinical trial and peer-reviewed research grants from Canadian Institutes of Health Research, Multiple Sclerosis Society of Canada, the National Multiple Sclerosis Society, and Public Health Agency of Canada. Dr Hanwell serves as a speaker for the Multiple Sclerosis Society of Canada and Teva Neuroscience.

Unlabeled Use of Products/Investigational Use Disclosure: Drs Marrie and Hanwell report no disclosures.

© 2013 American Academy of Neurology
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website